• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed

    2/16/21 4:02:05 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $TLRY alert in real time by email
    SC 13D/A 1 d119834dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 4)*

     

     

    Tilray, Inc.

    (Name of Issuer)

    Class 2 Common Stock

    (Title of Class of Securities)

    88688T 100

    (CUSIP Number)

    Brendan Kennedy

    2701 Eastlake Ave. E., 3rd Floor

    Seattle, WA 98102

    Telephone: (206) 395-7505

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    February 16, 2021

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 88688T 100

     

      1. 

     

    Name of Reporting Persons.

     

    Brendan Kennedy

      2.

     

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ☐         (b)  ☐

     

      3.

     

    SEC USE ONLY

     

      4.

     

    Source of Funds (See Instructions)

     

    AF

      5.

     

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

    ☐

      6.

     

    Citizenship or Place of Organization

     

    United States Citizen

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With:

      

      7.

      

    Sole Voting Power

     

    12,782,843 shares(1)

      

      8.

      

    Shared Voting Power

     

    0 shares

      

      9.

      

    Sole Dispositive Power

     

    12,782,843 shares (1)

      

    10.

      

    Shared Dispositive Power

     

    0 shares

    11.

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    12,782,843 shares (1)

    12.

     

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

    ☐

    13.

     

    Percent of Class Represented by Amount in Row (11)

     

    7.9% (2)

    14.

     

    Type of Reporting Person (See Instructions)

     

    IN

     

    (1)

    Consists of (1) 9,866,975 shares of Class 2 Common Stock held directly by Mr. Kennedy, (2) 2,634,053 shares of Class 2 Common Stock that are issuable upon the exercise of options held directly by Mr. Kennedy that are exercisable within 60 days of February 12, 2021, and (3) 234,940 shares of Class 2 Common Stock held directly by a limited liability company, of which Mr. Kennedy is the sole member and has sole voting and investment power decisions as it relates to such limited liability company.

     

    (2)

    Based on (1) 158,256,763 shares of Class 2 Common Stock that were outstanding as of December 15, 2020, set forth in the Issuer’s Current Report on Form 8-K filed with the SEC on December 21, 2020, (2) 2,634,053 shares of Class 2 Common Stock that are issuable upon the exercise of options held directly by Mr. Kennedy that are exercisable within 60 days of February 12, 2021, and (3) 46,875 shares of Class 2 Common Stock that are issuable upon the vesting of restricted stock units held directly by Mr. Kennedy that will vest within 60 days of December 15,

     

    2


    CUSIP No. 88688T 100

     

    Item 1.

    Security and Issuer.

    This Amendment No. 4 (“Amendment No. 4”) to Schedule 13D amends the statement on Schedule 13D filed on December 23, 2019 (the “Original Schedule 13D”), as amended by Amendment No. 1 as filed with the Securities and Exchange Commission on June 19, 2020 (“Amendment 1”), Amendment No. 2 as filed with the Securities and Exchange Commission on September 24, 2020, and Amendment No. 3 as filed with the Securities and Exchange Commission on October 16, 2020 (“Amendment 3” and together with the Original Scheduled 13D, Amendment No. 1, Amendment No. 2 and this Amendment No. 4, the “Schedule 13D”) with respect to the Class 2 Common Stock of Tilray, Inc. (the “Issuer”), having its principal executive office at 1100 Maughan Road, Nanaimo, BC, Canada. Except as otherwise specified in this Amendment No. 4, all items in the Schedule 13D, as amended by Amendment 1, Amendment 2, and Amendment No. 3, are unchanged. All capitalized terms used in this Amendment No. 4 and not otherwise defined herein have the meanings ascribed to such terms in the Original Schedule 13D.

    The Reporting Person is filing this Amendment No. 4 to report a decrease in the percentage of the class beneficially owned by the Reporting Person due to an increase in the aggregate number of outstanding securities of the Issuer.

     

    Item 5.

    Interest in Securities of the Issuer

     

      (a)

    State the aggregate number and percentage of the class of securities identified pursuant to Item 1 (which may be based on the number of securities outstanding as contained in the most recently available filing with the Commission by the issuer unless the filing person has reason to believe such information is not current) beneficially owned (identifying those shares which there is a right to acquire) by each person named in Item 2. The information should also be furnished with respect to persons who, together with any of the persons named in Item 2, comprise a group within the meaning of Section 13(d)(3) of the Act:

    The Reporting Person is the beneficial owner of 12,782,843 shares of Class 2 Common Stock, representing 7.9 % of the outstanding Class 2 Common Stock. The Reporting Person’s ownership includes (1) 9,866,975 shares of Class 2 Common Stock held directly by the Reporting Person, (2) 2,634,053 shares of Class 2 Common Stock that are issuable upon the exercise of options held directly by the Reporting Person that are exercisable within 60 days of February 12, 2021, and (3) 234,940 shares of Class 2 Common Stock held directly by an LLC, of which the Reporting Person is the sole member.

    The percentage in the foregoing paragraph is based on (1) 158,256,763 shares of Class 2 Common Stock that were outstanding as of December 15, 2020, set forth in the Issuer’s Form 8-K filed with the SEC on December 21, 2020, (2) 2,634,053 shares of Class 2 Common Stock that are issuable upon the exercise of options held directly by the Reporting Person that are exercisable within 60 days of February 11, 2021, and (3) 46,875 shares of Class 2 Common Stock that are issuable upon the vesting of restricted stock units held directly by the Reporting Person that will vest within 60 days of December 15, 2020.

     

    3


      (b)

    For each person named in response to paragraph (a), indicate the number of shares as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition. Provide the applicable information required by Item 2 with respect to each person with whom the power to vote or to direct the vote or to dispose or direct the disposition is shared:

    Regarding the number of shares as to which the Reporting Person has:

     

      a.

    Sole power to vote or to direct the vote: See line 7 of cover sheet.

     

      b.

    Shared power to vote or to direct the vote: See line 8 of cover sheet.

     

      c.

    Sole power to dispose or to direct the disposition: See line 9 of cover sheet.

     

      d.

    Shared power to dispose or to direct the disposition: See line 10 of cover sheet.

     

      (c)

    Describe any transactions in the class of securities reported on that were effected during the past sixty days or since the most recent filing of Schedule 13D (§240.13d-191), whichever is less, by the persons named in response to paragraph (a):

    Information with respect to transactions in the Securities which were effected within the past sixty days or since the most recent filing on Schedule 13D, whichever is less, by the Reporting Person is set forth below.

     

    Date of
    Transaction
             Type of
    Transaction
             Quantity          Class of Stock         

    Price Per Share

    (excluding

    commissions)

    07/31/2020        Cancellation        9,783*        Class 2
    Common Stock
           N/A
    11/04/2020        Sale        400,000        Class 2
    Common Stock
           $6.038**
    11/05/2020        Sale        400,000        Class 2
    Common Stock
           $7.434**
    11/06/2020        Sale        400,000        Class 2
    Common Stock
           $9.883**
    11/10/2020        Option Exercise        380,781        Class 2
    Common Stock
           $7.76
    01/01/2021        RSU Vesting        46,875        Class 2
    Common Stock
           N/A
    01/01/2021        Sale        12,777***        Class 2
    Common Stock
           N/A
    01/25/2021       Cancellation       3,428****      

    Class 2

    Common Stock

          N/A

    * Represents the aggregate number of shares cancelled pursuant to claim against shares held in escrow, including 163 shares held in escrow by an LLC of which the Reporting Person is the sole member.

    **Represents the weighted average sale price.

    ***Represents the number of shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of the RSU.

    **** Represents the aggregate number of shares cancelled pursuant to claim against shares held in escrow, including 57 shares held in escrow by an LLC of which the Reporting Person is the sole member.

     

    4


      (d)

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of an employee benefit plan, pension fund or endowment fund is not required:

    Not applicable.

     

      (e)

    If applicable, state the date on which the reporting person ceased to be the beneficial owner of more than five percent of the class of securities:

    Not applicable.

     

    5


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 16, 2021     By:*    
          Brendan Kennedy

     

    Date: February 16, 2021     *By:   /s/ Julia Stark
          Julia Stark, as Attorney-in-Fact

    This Schedule 13D was executed by Julia Stark on behalf of Brendan Kennedy pursuant to a Power of Attorney, a copy of which was filed the SEC on September 24, 2020.

     

    6

    Get the next $TLRY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLRY

    DatePrice TargetRatingAnalyst
    4/5/2024$2.25 → $2.75Neutral
    Alliance Global Partners
    11/2/2022$3.90Mkt Perform
    Bernstein
    7/29/2022$3.00Hold → Sell
    The Benchmark Company
    3/4/2022$9.00Hold → Buy
    Canaccord Genuity
    1/11/2022$7.40 → $6.90Neutral
    Cantor Fitzgerald
    1/7/2022$11.80 → $7.40Neutral
    Cantor Fitzgerald
    11/18/2021$10.00Underweight
    Barclays
    11/1/2021$18.00 → $11.80Overweight → Neutral
    Cantor Fitzgerald
    More analyst ratings

    $TLRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Simon Irwin D exercised 706,216 shares at a strike of $0.58 and covered exercise/tax liability with 374,295 shares, increasing direct ownership by 7% to 4,826,493 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:07:08 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Merton Carl A exercised 93,928 shares at a strike of $0.58 and covered exercise/tax liability with 49,782 shares, increasing direct ownership by 5% to 920,497 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:06:42 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Global General Counsel Gendel Mitchell exercised 93,928 shares at a strike of $0.58, covered exercise/tax liability with 49,782 shares and bought $3,496 worth of shares (6,000 units at $0.58), increasing direct ownership by 8% to 698,287 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:06:19 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    SEC Filings

    View All

    SEC Form 10-K filed by Tilray Brands Inc.

    10-K - Tilray Brands, Inc. (0001731348) (Filer)

    7/28/25 7:22:54 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Tilray Brands, Inc. (0001731348) (Filer)

    7/28/25 4:32:41 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

    8-K - Tilray Brands, Inc. (0001731348) (Filer)

    6/23/25 4:10:42 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Global General Counsel Gendel Mitchell exercised 93,928 shares at a strike of $0.58, covered exercise/tax liability with 49,782 shares and bought $3,496 worth of shares (6,000 units at $0.58), increasing direct ownership by 8% to 698,287 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    8/4/25 4:06:19 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    President and CEO Simon Irwin D bought $100,106 worth of shares (165,000 units at $0.61), increasing direct ownership by 4% to 3,941,633 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    7/30/25 6:52:32 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Chief Financial Officer Merton Carl A bought $19,939 worth of shares (33,500 units at $0.60), increasing direct ownership by 4% to 798,069 units (SEC Form 4)

    4 - Tilray Brands, Inc. (0001731348) (Issuer)

    7/30/25 3:12:46 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tilray Brands Reconfirms Strategy to Regain Nasdaq Compliance; Requests Extension to Meet Listing Requirements

    NEW YORK and LEAMINGTON, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle consumer packaged goods company at the forefront of the cannabis, beverage, and wellness industries, today announced that the Company has submitted an application requesting an extension to regain compliance with Nasdaq's listing standards regarding its price per share. The Company is evaluating several options including, but not limited to, a stockholder-approved Reverse Stock Split to address capital structure and maintain adherence to Nasdaq's continued listing requirements. Irwin Simon, Chief Executive Officer, Tilray Brands,

    8/14/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Medical Forms Strategic Partnership in Italy to Broaden Access to Medical Cannabis Extracts

    NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (NASDAQ:TLRY, TSX:TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, announced today that its wholly-owned subsidiary, FL Group S.R.L., has entered into a strategic partnership with L. Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A. ("Molteni"), an Italian pharmaceutical firm specializing in pain therapies and substance dependence. The partnership is designed to broaden the availability of Tilray Medical cannabis extracts for patients across Italy. M

    8/13/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Expands Hemp-Derived Delta-9 THC Beverage Lineup with 10mg Drinks from Fizzy Jane's and Happy Flower Brands

    NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray") (NASDAQ:TLRY, TSX:TLRY) is building on the momentum of its hemp-derived Delta-9 THC (HDD9) beverage portfolio with new 10mg format extensions from its brands: Fizzy Jane's and Happy Flower. Fizzy Jane's, the sparkling seltzer line that debuted this spring in Georgia, North Carolina, and South Carolina, is now available in a 10mg HDD9 THC format, enhancing the buzz while keeping the same crisp, fruit-forward refreshment fans love. With 15 calories or fewer per can, Fizzy Jane's seltzers come in three vibrant flavors: Vanilla, Blood Orange, and Lemon Lime. The new 10mg drinks join the original 5mg lineup and are now

    8/12/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners reiterated coverage on Tilray with a new price target

    Alliance Global Partners reiterated coverage of Tilray with a rating of Neutral and set a new price target of $2.75 from $2.25 previously

    4/5/24 7:39:50 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Bernstein initiated coverage on Tilray with a new price target

    Bernstein initiated coverage of Tilray with a rating of Mkt Perform and set a new price target of $3.90

    11/2/22 6:37:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray downgraded by The Benchmark Company with a new price target

    The Benchmark Company downgraded Tilray from Hold to Sell and set a new price target of $3.00

    7/29/22 7:19:40 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Tilray Brands Inc. (Amendment)

    SC 13G/A - Tilray Brands, Inc. (0001731348) (Subject)

    2/13/23 1:34:44 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G filed by Tilray Brands Inc.

    SC 13G - Tilray Brands, Inc. (0001731348) (Subject)

    2/10/23 4:41:36 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D filed by Tilray Brands Inc.

    SC 13D - Tilray Brands, Inc. (0001731348) (Filed by)

    7/22/22 4:30:22 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Financials

    Live finance-specific insights

    View All

    Tilray Brands Reports Fourth Quarter and Fiscal 2025 Financial Results

    Fiscal Year Net Revenue of $821 Million, $834 Million in Constant Currency, Strategic Decisions Impacted Revenue by $35 Million Q4 Consolidated Adjusted EBITDA is the 2nd Highest in the Company's History International Cannabis Revenue Increased 71% in Q4 and 19% for the Fiscal Year; Canadian Cannabis Remained #1 by Revenue in the Fiscal Year; Global Cannabis Gross Margin Increased by ~700 Basis Points in the Fiscal Year 19% Revenue Growth in Tilray Beverages with $241 Million for the Fiscal Year 9% Revenue Growth in Tilray Wellness with $60 Million for the Fiscal Year Strong Balance Sheet with $256 Million Available in Cash and Marketable Securities; Total Debt Repayments of ~$100 Milli

    7/28/25 4:30:13 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on July 28, 2025

    NEW YORK and LEAMINGTON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced that the Company will release its financial results for the fourth quarter and full fiscal year ended May 31, 2025, after market close on Monday, July 28, 2025. Live Conference Call and Audio Webcast Tilray will host a live conference call, which will be webcast, to discuss these results at 4:30 PM Eastern Time. The webcast can be accessed on the Events & Presentations section of Tilray's Investor Relations websi

    7/9/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Tilray Brands Reports Q3 Fiscal 2025 Financial Results

    Tilray Confirms No Current Impact of Tariffs Generated Net Revenue of $186 Million in the Third Quarter, $193 Million in Constant Currency; Strategic Initiatives and SKU Rationalization Impacted Revenue by $13 Million Tilray Beverage Expands U.S. Distribution of Hemp-Derived THC Drinks Across 10 States, Increases Project 420 Cost Savings Plan to $33 Million Tilray Cannabis Increased Gross Margins by 800 bps, Remains the Leader in Canada by Sales Performance, and Generates Strong Sales Growth in Germany Strengthens Balance Sheet with Convertible Note Reduction of $58 Million and Total Debt Reduction of $71 Million, $248 Million Available in Cash and Marketable Securities NEW Y

    4/8/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    $TLRY
    Leadership Updates

    Live Leadership Updates

    View All

    Terrapin Beer Co. Celebrates 20 Years of Iconic Wake-n-Bake Beer with Exciting Wake-n-Bake Off Event in Athens, GA

    ATHENS, Ga., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Terrapin Beer Co., a Tilray Beverages craft beer brand under Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), is excited to announce the 20th anniversary of its Wake-n-Bake Coffee Oatmeal Imperial Stout seasonal beer and the annual Wake-n-Bake Off event on Sunday, January 26th, 2025, at the Terrapin taproom in Athens, GA. In celebration of its 20th anniversary, guests will have the chance to observe local restaurants competing to craft the finest dish featuring Terrapin's renowned Wake-n-Bake Beer. This event highlights culinary innovation and fosters community engagement through an array of sweet and savory tastings that showcase the rich flavor

    1/23/25 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Blue Point Brewing Launches Big Mo Brew to Raise Funds and Awareness for Men's Health During Movember

    PATCHOGUE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Blue Point Brewing Company, Long Island's original craft brewery and subsidiary of Tilray Brands, (NASDAQ:TLRY, TSX:TLRY), is proud to announce the continuation of its men's health awareness campaign in support of Movember. The month shines a light on key men's health issues—mental health, prostate cancer, and testicular cancer—encouraging open conversations and proactive engagement. To honor the initiative, Blue Point Brewing announced the special release of its classic double IPA, Big Mo, available at our brewery and retailers in Long Island, New York. This hazy double IPA, featuring prominent mosaic hops and an ABV of 8.0%, proud

    10/22/24 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care

    Breckenridge Brewery Opens New Location in Fort Collins, Colorado

    FORT COLLINS, Colo., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Breckenridge Brewery, a Colorado-based craft brewer with over 30 years of experience brewing approachable, well-balanced beers, announces the opening of its new brewery location in Fort Collins. With doors opening in early August 2024, the new 10,000-square-foot Breckenridge Brewery offers a full restaurant experience and a new vibrant atmosphere in the heart of Fort Collins for all to enjoy. The new location will be a full-service restaurant, upholding the Breckenridge Brewery legacy while ushering in new opportunities for innovation and community collaboration. With a menu boasting a diverse range of culinary delights designed to co

    8/5/24 7:00:00 AM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care